Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Denver news in your inbox
Catch up on the most important stories affecting your hometown with Axios Denver
Des Moines news in your inbox
Catch up on the most important stories affecting your hometown with Axios Des Moines
Minneapolis-St. Paul news in your inbox
Catch up on the most important stories affecting your hometown with Axios Twin Cities
Tampa Bay news in your inbox
Catch up on the most important stories affecting your hometown with Axios Tampa Bay
Charlotte news in your inbox
Catch up on the most important stories affecting your hometown with Axios Charlotte
Auris Surgical Robotics has raised $280 million in new VC funding at what sources tell Axios was a pre-money valuation of around $1 billion. As its name suggests, the company's plan is to make robotics for use in human surgeries, with CEO Fred Moll saying today that the first targeted disease will be lung cancer:
"The reason lung cancer is so deadly is that the diagnostic and treatment processes are ineffective. The majority of lung cancer patients are diagnosed in late stage, when the cancer has already spread beyond its primary location. With our technology, physicians will be able to access early stage lung cancer without incisions, allowing accurate diagnosis and targeted treatment."
Investors: We're told that Cotaue Management led the round, and was joined by Viking Global, Partner Fund Management, Section 32 and return backers Lux Capital, Mithril Capital Management and Highland Capital Partners.